Recommended composition of influenza virus vaccines for use in the 2022-2023 northern hemisphere influenza season
Recommended composition of influenza virus vaccines for use in the 2022-2023 northern hemisphere influenza season
The WHO recommends that quadrivalent vaccines for use in the 2022-2023 northern hemisphere influenza season contain the following:
Egg-based vaccines
an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
an A/Darwin/9/2021 (H3N2)-like virus;
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
Cell culture- or recombinant-based vaccines
an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
an A/Darwin/6/2021 (H3N2)-like virus;
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
The WHO recommends that trivalent vaccines for use in the 2022-2023 northern hemisphere influenza season contain the following:
Egg-based vaccines
an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
an A/Darwin/9/2021 (H3N2)-like virus; and
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
Cell culture- or recombinant-based vaccines
an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
an A/Darwin/6/2021 (H3N2)-like virus; and
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus